-
Jul 31, 2024 | 
lexology.com | Theresa C. Carnegie |Rachel Alexander |Madison Castle |Xavier G. Hardy |Stephnie A. John |Alison Peters | +8 more
The PBM regulatory landscape is rapidly evolving at both federal and state levels, making it critical for our clients involved in the PBM space to stay apprised of developments in the industry as they happen. Our team actively monitors these developments to provide you with this PBM Policy and Legislative Update. This update builds on prior issues and highlights federal and state activity from January 2024 through June 2024.
-
Jul 31, 2024 | lexology.com | Theresa C. Carnegie |Rachel Alexander |Madison Castle |Xavier G. Hardy |Stephnie A. John |Alison Peters | +8 more
The PBM regulatory landscape is rapidly evolving at both federal and state levels, making it critical for our clients involved in the PBM space to stay apprised of developments in the industry as they happen. Our team actively monitors these developments to provide you with this PBM Policy and Legislative Update. This update builds on prior issues and highlights federal and state activity from January 2024 through June 2024.
-
Jul 18, 2024 | 
mondaq.com | Stephnie A. John
In our previous Mintz IRA Update, we
covered the Biden administration's proposal exploring the use
of "march-in rights" granted under the Bayh-Doyle Act
(the "Act") to seize pharmaceutical patents if the
administration believes that a pharmaceutical product is not
available to the public at a reasonable price.
-
Jul 16, 2024 | 
jdsupra.com | Stephnie A. John
In our previous Mintz IRA Update, we covered the Biden administration’s proposal exploring the use of “march-in rights” granted under the Bayh-Doyle Act (the “Act”) to seize pharmaceutical patents if the administration believes that a pharmaceutical product is not available to the public at a reasonable price.
-
Jul 16, 2024 | 
jdsupra.com | Madison Castle |Samantha Hawkins |Stephnie A. John
Since our last edition of the Mintz IRA Update, the Medicare Drug Price Negotiation Program (the “Negotiation Program” or “Program”) and related maximum fair price (MFP) negotiation process for each of the 10 high-expenditure Medicare Part D drugs selected for negotiation (the “Selected Drugs”) has gone into full swing.
-
Jul 15, 2024 | 
natlawreview.com | Stephnie A. John
The Medicare Drug Price Negotiation Program (the “Negotiation Program” or “Program”) and related maximum fair price (MFP) negotiation process for each of the 10 high-expenditure Medicare Part D drugs selected for negotiation (the “Selected Drugs”) has gone into full swing.
-
Jul 15, 2024 | 
lexology.com | Tara Dwyer |Lauren M. Moldawer |David Gilboa |Samantha Hawkins |Stephnie A. John |Matthew Tikhonovsky
The passage of the Inflation Reduction Act of 2022 (IRA) marked a significant milestone in Congress’s ongoing efforts to address escalating health care costs. While the IRA aims to rein in government spending on Medicare and to lower point-of-sale prescription drug costs for Medicare beneficiaries, its implementation, and adoption of the redesigned Medicare Part D program has sparked a cascade of consequences for Medicare Part D plan sponsors (“PDPs”), beneficiaries, and manufacturers.
-
Apr 1, 2024 | 
mondaq.com | Stephnie A. John |Daniel Cody |Deborah A. Daccord |Karen S. Lovitch
States are increasingly exercising regulatory oversight of
health care transactions by enacting laws requiring prior notice or
approval of certain health care transactions. Currently, 15 states
have enacted health care transaction review laws applicable to
for-profit transactions. On Wednesday, March 20, 2024, Mintz
members Daniel A. Cody, Deborah A. Daccord, and Karen S.
-
Mar 28, 2024 | 
jdsupra.com | Daniel Cody |Deborah A. Daccord |Stephnie A. John
States are increasingly exercising regulatory oversight of health care transactions by enacting laws requiring prior notice or approval of certain health care transactions. Currently, 15 states have enacted health care transaction review laws applicable to for-profit transactions. On Wednesday, March 20, 2024, Mintz members Daniel A. Cody, Deborah A. Daccord, and Karen S.
-
Mar 27, 2024 | 
lexology.com | Stephnie A. John |Daniel Cody |Deborah A. Daccord |Karen S. Lovitch
States are increasingly exercising regulatory oversight of health care transactions by enacting laws requiring prior notice or approval of certain health care transactions. Currently, 15 states have enacted health care transaction review laws applicable to for-profit transactions. On Wednesday, March 20, 2024, Mintz members Daniel A. Cody, Deborah A. Daccord, and Karen S.
